News & Videos - SOTERA HEALTH CO.

SALT LAKE CITY, March 04, 2025 (GLOBE NEWSWIRE) -- Nelson Labs, a Sotera Health company and a global leader in microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries, now performs product-sterility testing through rapid microbiological methods (RMMs) at three laboratory sites located in the United States and Europe . Nelson Labs’ testing solution is unique in that it supports a broad range of both medical devices and...

2024 net revenues increased 4.9% to $1.10 billion , compared to 2023; or 5.4% on a constant currency basis 2024 net income of $44 million or $0.16 per diluted share, compared to 2023 2024 Adjusted EBITDA (1) increased 3.9% to $549 million, compared to 2023; or 4.6% on a constant currency basis 2024 Adjusted EPS (1) of $0.70, a decrease of $0.02 per diluted share, compared to 2023 Full-year 2025 outlook of 4.0% - 6.0% net revenues growth and 4.5% - 6.5% Adjusted EBITDA growth, both on a constant...

CLEVELAND, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the fourth-quarter and full-year ended December 31, 2024 before the market opens on Thursday, February 27, 2025. Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to...

CLEVELAND, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, is presenting today at the 43rd Annual J.P. Morgan Healthcare Conference. During the presentation, Chairman and CEO Michael B. Petras, Jr. will be providing an update on Sotera Health’s business. “I am pleased to announce...

CLEVELAND, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (NASDAQ: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced that Chairman and CEO Michael B. Petras, Jr. will present at the 43 rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 at 11:15 a.m. Eastern Time. Mr. Petras, Jon Lyons, Senior Vice President...

CLEVELAND, Ohio, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, is pleased to announce today the appointment of Vincent K. Petrella as Lead Independent Director, effective January 2, 2025. Mr. Petrella, who has served on Sotera Health Company’s Board of Directors since 2020, brings a wealth of experience and a deep...

CLEVELAND, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, will hold an Investor Day in New York City where Sotera Health’s management team will discuss the Company’s strategic positioning and outline future growth plans. Management will take questions from a live audience during two question-and-answer sessions. “The...

Q3 2024 net revenues of $285 million increased 8.5%, compared to Q3 2023 Q3 2024 net income of $17 million or $0.06 per diluted share, compared to net loss of $14 million or $0.05 per diluted share in Q3 2023 Q3 2024 Adjusted EBITDA ( 1 ) of $146 million increased 9.0%, compared to Q3 2023 Q3 2024 Adjusted EPS ( 1 ) of $0.17 increased $0.01 per diluted share, compared to Q3 2023 Reaffirming 2024 Net Revenue and Adjusted EBITDA outlook ranges CLEVELAND, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Sotera...

CLEVELAND, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the third-quarter ended September 30, 2024 before the market opens on Tuesday, November 5, 2024. Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to discuss the...

CLEVELAND, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC) (the “Company”) today announced the launch of a secondary offering (the “Offering”) of 25,000,000 shares of its common stock, par value $0.01 per share. All 25,000,000 shares are being offered for sale by certain affiliates of Warburg Pincus LLC (“Warburg Pincus”) and GTCR LLC (“GTCR”) as selling stockholders. No other entities, and no individuals, are selling shares in the Offering. It is expected...

Q2 2024 net revenues of $277 million increased 8%, compared to Q2 2023 Q2 2024 net income of $9 million or $0.03 per diluted share, compared to net income of $24 million or $0.08 per diluted share in Q2 2023 Q2 2024 Adjusted EBITDA ( 1 ) of $137 million increased 7%, compared to Q2 2023 Q2 2024 Adjusted EPS (1) of $0.19 declined $0.01 per diluted share, compared to Adjusted EPS of $0.20 in Q2 2023 Successfully refinanced debt structure, extending debt maturities to 2031 Reaffirming 2024 outlook...

CLEVELAND, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Christopher Simon as a new independent director to its Board of Directors. Mr. Simon will serve as a member of the Leadership Development and Compensation Committee of the Board of Directors. For approximately the past eight years, Mr....

CLEVELAND, July 22, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the second-quarter ended June 30, 2024 before the market opens on Monday, August 5, 2024. Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to discuss the Company’s...

CLEVELAND, May 30, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced that its direct subsidiary has successfully closed a new senior secured Term Loan B facility in an aggregate principal amount of $1.51 billion (the “TLB”) as well as an issuance of senior secured notes in an...

Q1 2024 net revenues increased 12.5% to $248 million, compared to Q1 2023 Q1 2024 net income of $6 million or $0.02 per diluted share, comp ared to net income of $3 million or $0.01 per diluted share in Q1 2023 Q1 2024 Adjusted EBITDA ( 1 ) increased 13.7% to $112 million, compared to Q1 2023 Q1 2024 Adjusted EPS (1) of $0.13 compared to Adjusted EPS of $0.13 in Q1 2023 Company reaffirms 2024 outlook CLEVELAND, May 02, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the...

CLEVELAND, April 11, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the first-quarter ended March 31, 2024 before the market opens on Thursday, May 2, 2024. Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to discuss the Company’s...

CLEVELAND, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC) (the “Company”) today announced the pricing of its secondary offering (the “Offering”) of 25,000,000 shares of its common stock, par value $0.01 per share, at a price to the public of $14.75 per share. All 25,000,000 shares are being offered by selling stockholders, which include certain affiliates of Warburg Pincus LLC and GTCR LLC, as well as two members of management and one member of the Board of...

CLEVELAND, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (the “Company”) today announced the launch of a secondary offering (the “Offering”) of 25,000,000 shares of its common stock, par value $0.01 per share. All 25,000,000 shares are being offered for sale by selling stockholders, which include affiliates of Warburg Pincus LLC and GTCR, LLC, as well as two members of management and one member of the Board of Directors of the Company. In addition, the selling stockholders have...

2023 net revenues increased 4.5% to $1.05 billion , compared to 2022 2023 net income of $51 million or $0.18 per diluted share 2023 Adjusted EBITDA (1) increased 4.3% to $528 million 2023 Adjusted EPS (1) decreased $0.15 to $0.81 per diluted share Full-year 2024 outlook of 4.0% - 6.0% growth for Net Revenues and Adjusted EBITDA CLEVELAND, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical...

CLEVELAND, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the fourth-quarter and full-year ended December 31, 2023 before the market opens on Tuesday, February 27, 2024. Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to...